CN101805355B - Thienopyridone derivative, preparation method and uses thereof - Google Patents
Thienopyridone derivative, preparation method and uses thereof Download PDFInfo
- Publication number
- CN101805355B CN101805355B CN2010101846423A CN201010184642A CN101805355B CN 101805355 B CN101805355 B CN 101805355B CN 2010101846423 A CN2010101846423 A CN 2010101846423A CN 201010184642 A CN201010184642 A CN 201010184642A CN 101805355 B CN101805355 B CN 101805355B
- Authority
- CN
- China
- Prior art keywords
- compound
- thtp
- ketone
- pyridines
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention, belonging to the technical field of anti-malignant tumor medicines, provides a thienopyridone derivative having the structure shown as formula I and pharmaceutically acceptable salts thereof, wherein R1 and R2 are defined as specification. The invention further relates a preparation method of the compound, and simultaneously discloses pharmaceutical compositions with the compound or pharmaceutically acceptable salts thereof as effective active ingredient as well as uses of the pharmaceutical compositions as anti-malignant tumor medicines,.
Description
Technical field
The invention belongs to medical technical field, or rather, relate to one type and have compound of anticarcinogenesis and preparation method thereof.
Background technology
Cancer is one of main killer of human health, and its mortality ratio ranked second the position in China position of ranking forefront in the world.According to World Health Organization statistics, global cancer mortality number in 2007 reaches 7,900,000 (account for all death tolls 13%), and lung cancer, cancer of the stomach, liver cancer, colorectal carcinoma and breast cancer are the arch-criminals of annual most of cancer mortalities.In recent years, because the cancer risk factors such as abuse of urban air pollution, overweight or obesity, alcohol tobacco are on the rise, cause the sickness rate of cancer to rise year by year.In developing country, along with the reduction of transmissible disease death and child mortality, more people's life-time dilatations, the burden of cancer also increases thereupon.Pharmacological agent is one of main treatment means of cancer, and the searching of cancer therapy drug is the popular domain of scientists study always.At present being used for anticancer medicine clinically has hundreds of; Prolong cancer patients's life effectively or improved cancer patients's life quality; But most drug is a cell toxicity medicament, and selectivity is not high, when eliminating tumour cell, normal cell is also had major injury; Cause the intensive toxic side effects, and have the resistance problem.In addition, existing chemicals is unsatisfactory to the result of treatment of most solid tumors.Therefore, seeking the new type anticancer medicine shoulders heavy responsibilities.
Summary of the invention
One object of the present invention is, open Thienopyridone analog derivative and pharmaceutical salts thereof.
Another object of the present invention is that disclosing with Thienopyridone derivative and pharmaceutical salts thereof is the pharmaceutical composition of main active ingredient.
A further object of the present invention is, discloses the preparation method of Thienopyridone derivative and pharmaceutical salts thereof.
A further object of the invention is, discloses Thienopyridone derivative and pharmaceutical salts thereof, as the application of medicine for resisting malignant tumors, particularly in the purposes that is used to prepare aspect treatment lung cancer, mammary cancer, liver cancer, the cancer of the stomach medicine.
The present invention is specifically related to the compound and the pharmacy acceptable salt thereof of general formula I structure:
Wherein:
n＝1，2；
R
1, R
2Be hydrogen, C
1-C
3Alkyl, halogen, halogenated methyl.
C of the present invention
1-C
3Alkyl and halogen, the concrete represent methylidene of halogenated methyl, ethyl, propyl group, sec.-propyl, fluorine, chlorine, trifluoromethyl etc.
The compound that the present invention relates to formula I structure, wherein part of compounds is:
(2-(4-phenylpiperazine-1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone also for I-1 5-;
(2-(4-p-methylphenyl piperazine-1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone also for I-2 5-;
(2-(the adjacent fluorophenyl piperazine of 4--1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone also for I-3 5-;
(2-(4-(2, the 3-dichlorophenyl) piperazine-1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone also for I-4 5-;
(2-(4-(3-trifluoromethyl) piperazine-1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone also for I-5 5-;
(3-(4-(2, the 3-dichlorophenyl) piperazine-1-yl)-3-oxopropyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone also for I-6 5-;
(3-(4-(2-fluorophenyl) piperazine-1-yl)-3-oxopropyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone also for I-7 5-.
The compound with formula I structure or its pharmacy acceptable salt among the present invention mean: the salt that The compounds of this invention is become with mineral acid, organic acid.Wherein preferred especially salt is: hydrochloride, hydrobromate, hydriodate, vitriol, hydrosulfate, phosphoric acid salt, acetate, propionic salt, butyrates, lactic acid salt, mesylate, tosilate, PHENRAMINE MALEATE, benzoate, SUMATRIPTAN SUCCINATE, tartrate, Citrate trianion, fumarate, taurate or the like.
The preparation route of formula I compound:
Wherein X is a halogen.
Substituted-piperazinyl compounds and halogen acyl halide are in methylene dichloride, trichloromethane or toluene; In the presence of acid binding agents such as triethylamine, pyridine, salt of wormwood, yellow soda ash, sodium hydrogencarbonate, saleratus, Pottasium Hydroxide, sodium hydroxide ,-30 ℃～35 ℃ reactions make key intermediate.Midbody again with compound 5; 6,7,7a-THTP also [3; 2-c] pyridine-2 (4H)-ketone; In methylene dichloride, trichloromethane or toluene, in the presence of acid binding agents such as triethylamine, pyridine, salt of wormwood, yellow soda ash, sodium hydrogencarbonate, saleratus, Pottasium Hydroxide, sodium hydroxide, 0 ℃～90 ℃ reactions make I.
Reaction is made various midbodys or products therefrom be dissolved in a kind of among ether, DMF, acetone, methyl alcohol, ethanol, ETHYLE ACETATE or the DMSO, dropping inorganic acid or organic acid solution are processed pharmacy acceptable salt.
Specifically be that all cpds is dissolved in a kind of among ether, DMF, acetone, methyl alcohol, ethanol, ETHYLE ACETATE or the DMSO, the dripping hydrochloric acid diethyl ether solution is processed hydrochloride to pH=2 under ice-water bath; Or all cpds is dissolved in a kind of among ether, DMF, acetone, methyl alcohol, ethanol, ETHYLE ACETATE or the DMSO, and adding and wait a mole taurine, heated and stirred gets its taurate; Or all cpds is dissolved in a kind of among ether, DMF, acetone, methyl alcohol, ethanol, ETHYLE ACETATE or the DMSO, drips concentrated sulfuric acid solution down to pH=3, process vitriol in ice-water bath, or the like.
This compounds is effective for the treatment human malignancies.Although compound of the present invention can be without the direct administration of any preparation, described all cpds preferably uses with the form of pharmaceutical prepn, and route of administration can be non-enteron aisle approach (like vein, muscle administration) and oral administration.
The preparation of pharmaceutical compositions of The compounds of this invention is following: use standard and conventional technology; Acceptable solid or liquid vehicle are combined, and make it at random with technology of pharmaceutics on acceptable auxiliary and vehicle combine to be prepared into particulate or microballoon.Solid dosage comprises tablet, discrete particles, capsule, slow releasing tablet, sustained release pellet or the like.Solid carrier can be at least a material, and it can serve as thinner, flavouring agent, solubilizing agent, lubricant, suspension agent, tackiness agent, disintegrating agent and coating agent.Inert solid carrier comprises trimagnesium phosphate, Magnesium Stearate, smoothers sugar, lactose, pectin, Ucar 35, Polysorbate 80, dextrin, starch, gelatin, cellulose substances for example methylcellulose gum, Microcrystalline Cellulose, low melt point paraffin, polyoxyethylene glycol, N.F,USP MANNITOL, theobroma oil etc.Liquid dosage form comprises solvent, suspension-s for example injection, pulvis or the like.
The amount of the active ingredient that contains in pharmaceutical composition and the unit dosage form (The compounds of this invention) can specifically be applied according to patient's the state of an illness, the situation of diagnosis, and the amount of used compound or concentration are regulated in the scope of a broad.Usually, the weight range of active compound is 0.5%～90% (weight) of compsn, and another preferred range is 0.5%-70%.
Compound or its pharmacy acceptable salt with formula I structure of the present invention has the obvious suppression effect to tumour in external, body.
External antitumor action
(1) experimental technique:
Adopt classical cytotoxic activity vitro detection method mtt assay, detect the cell proliferation toxicity of Thienopyridinone derivatives the human tumor cells of vitro culture.
(2) experiment material:
Laboratory sample: Thienopyridinone derivatives is provided by contriver's self-control.Sample is with the DMSO hydrotropy during experiment, and serum-free DMEM substratum is diluted to desired concn, and sample segment solution is suspension.
Main agents: MTT, the packing of Amresco company, lot number: 04M0904; Complete DMEM substratum, Gibco Company products, lot number: 1290007; Calf serum, Lanzhou people's marine life, lot number: 20060509; Trypsinase, the packing of Amresco company, lot number: 016B0604; Fluorouracil Injection, 0.25g/10mL (propping up), lot number: 0512022, Tianjin gold credit amino acid ltd.
Laboratory apparatus: Bechtop, Suzhou Decontamination Equipment Plant; CO
2Incubator, Thermo company, model: HERA Cell150; Inverted microscope, Carl Zeiss company, model: Axiovert 200; Enzyme-linked immunosorbent assay instrument, TECAN company, model: Sunrise; Whizzer, Kerdro company, model: Heraeus.
Cell strain: lung cancer A-549 cell, liver cancer SMMC-7721 cell, mammary cancer MCF-7 cell, adenocarcinoma of stomach SGC-7901 cell, all available from Shanghai cell research institute of the Chinese Academy of Sciences.
(3) experimental procedure:
Cell cultures: tumor cell inoculation is containing 10% calf serum, in the DMEM nutrient solution of 100IU/mL penicillin G sodium salt and 100ug/mL Vetstrep, places 37 ℃, 100% relative humidity, contains 5%CO
2Incubator in, it is subsequent use after 3 times to go down to posterity.
Mtt assay is measured: the cell in the vegetative period of taking the logarithm; Behind 0.25% tryptic digestion (suspension cell need not digest); Be suspended in the DMEM nutrient solution that contains 10% calf serum, blow and beat into single cell suspension gently with the glass dropper, microscopically is with blood cell counts plate numeration viable cell.(cell concn is adjusted into 6～10 * 10 to the every hole of 96 well culture plates inoculating cell suspension 90 μ L
4Individual/mL), at 37 ℃, 100% relative humidity, contain 5%CO
2, 95% air incubator cultivate 24h after, every hole adds 10 μ L soups (final concentration is made as: 40 μ g/mL, 20 μ g/mL, 10 μ g/mL, 5 μ g/mL and five concentration of 2.5 μ g/mL).In addition, each concentration is established negative control (isoconcentration DMSO) and blank background (not adding cell), and each group is all established 6 multiple holes.Cultured continuously 24h again, every then hole adds the MTT solution 10 μ L of 5mg/mL, and after continuing to cultivate 4h, the careful suction removed supernatant (suspension cell needs earlier centrifugally, inhales and removes supernatant).Every hole adds DMSO 100 μ L, puts micro oscillator concussion 5min so that crystallization is dissolved fully, and the single wavelength colorimetric of ELIASA 492nm is measured the OD value.Calculate inhibitory rate of cell growth as evaluation index with following method.
Inhibiting rate (%)=[1-(experimental group OD average-blank control group OD average)/(control group OD average-blank control group OD average)] * 100%.According to inhibitory rate of cell growth, calculate IC with the straight-line regression method
50Value.
(4) experimental result: see table 1.
The IC of the tumour cell of table 1. pair vitro culture
50(μ g/mL)
(5) conclusion:
According to above-mentioned in vitro tests result, we can find out that the compound with general formula I structure has stronger restraining effect to above-mentioned 4 kinds of human tumor cells.
Intravital antitumor action
(1) experiment material:
Sample: I-4 is provided by contriver's self-control.
Cell strain: liver cancer H22 cell, all available from Shanghai cell research institute of the Chinese Academy of Sciences.
Positive control drug: endoxan, lot number: 07020121, Hengrui Medicine Co., Ltd., Jiangsu Prov..
Instrument: PB303-N type per mille electronic balance, Mettler Toledo Inc. produces.
Animal: Kunming mouse, the SPF level, male and female half and half, body weight 18-22g purchases in Institute of Radiation Medicine, Chinese Academy of Medical Sciences, conformity certification number: SCXK (Tianjin) 2005-0001.
(2) experimental technique:
Get abdominal cavity inoculation knurl strain 9 days, tumor growth is good, the tangible tumor-bearing mice of abdominal tympanites; Ascites is drawn in aseptic technique down; Be made into the cancer cells suspension by saline water dilution in 1: 3, in all experiment mice right fore armpit subcutaneous vaccinations (0.2mL/ mouse), all operations is accomplished in 30min.To inoculate knurl liquid mouse next day by the body weight random packet, i.e. lotus knurl control group, endoxan group (25mg/kg), I-4 organizes (100mg/kg, 50mg/kg).The equal intraperitoneal injection of each administration group, once a day, control group gives with volume saline water.Mouse successive administration 10 days behind the last administration 24h, takes off cervical vertebra and puts to death, and peels off tumour, takes by weighing knurl and weighs, and calculates and respectively organizes heavy MV of mouse tumor and inhibiting rate.
Inhibiting rate=[(the average knurl of the average knurl weight-experimental group of control group is heavy)/average knurl of control group is heavy] * 100%
(3) result:
Table 2. pair H22 tumor-bearing mice knurl heavily reaches the influence
of inhibiting rate
(4) conclusion:
Can find out that from above-mentioned animal vivo test result I-4 has certain restraining effect to the tumor growth of H22 tumor-bearing mice.Wherein during 100mg/kg dose groups intraperitoneal injection, inhibition rate of tumor growth all is better than positive control.
Embodiment
Below in conjunction with embodiment the present invention is done further explanation, it is indicative that embodiment is merely, and means that never it limits scope of the present invention by any way.Described compound is through performance liquid chromatography (HPLC), and thin-layer chromatography (TLC) detects.Can adopt subsequently such as ir spectra (IR), nuclear magnetic resonance spectrum (
1H NMR,
13C NMR), mass spectrum (MS) etc. is further proved conclusively its structure.
Embodiment 1:
Midbody
1Preparation
In the reaction flask that stirring, condensing surface, TM are housed, add 4-phenylpiperazine 16.2g, it is dissolved, be cooled to-30 ℃ under stirring, add Anhydrous potassium carbonate 41.5g with the 30mL methylene dichloride.Chloroacetyl chloride 11.3g is dissolved in the 25mL methylene dichloride, slowly is added dropwise to reaction system, dropwise, continue reaction 2 h (the flaggy demonstration reacts completely) down in-10 ℃.With 3 * 50mL water washing reaction solution, obtain dichloromethane layer, use the SODIUM SULPHATE ANHYDROUS 99PCT thorough drying, to filter, methylene dichloride is to the greatest extent steamed in decompression, promptly gets colorless oil product 21.0g (HPLC:98.5%).Rf=0.56 [single-point, developping agent: v (sherwood oil): v (ETHYLE ACETATE)=2: 1].
1H?NMR(CDCl
3，400MHz)δ：3.452～3.457(m，2H)，3.460～3.465(m，2H)，3.628～3.633(m，4H)，4.298(s，2H)，6.543～6.545(m，1H)，6.722～6.725(m，2H)，7.436～7.440(m，2H)。
Embodiment 2:
Midbody
2Preparation
In the reaction flask that stirring, condensing surface, TM are housed, add p-methylphenyl piperazine 17.6g, it is dissolved, be cooled to-20 ℃ under stirring, add triethylamine 30.4g with the 40mL trichloromethane.Bromoacetyl bromide 20.2g is dissolved in the 30mL trichloromethane, slowly is added dropwise to reaction system, dropwise, continue reaction 4h (the flaggy demonstration reacts completely) down in 0 ℃.With 3 * 80mL water washing reaction solution, obtain the trichloromethane layer, use the SODIUM SULPHATE ANHYDROUS 99PCT thorough drying, to filter, trichloromethane is to the greatest extent steamed in decompression, promptly gets colorless oil product 26.8g (HPLC:98.9%).Rf=0.60 [single-point, developping agent: v (sherwood oil): v (ETHYLE ACETATE)=2: 1].
1H?NMR(CDCl
3，400MHz)δ：2.517～2.519(s，3H)，3.453～3.458(m，2H)，3.462～3.466(m，2H)，3.631～3.636(m，4H)，4.301(s，2H)，6.629～6.631(d，2H)，7.138～7.140(d，2H)。
Embodiment 3:
Midbody
3Preparation
With reference to the method for embodiment 1, replace the 4-phenylpiperazine with adjacent fluorophenyl piperazine, with the chloroacetyl chloride reaction, get colorless oil product (HPLC:99.6%).Rf=0.58 [single-point, developping agent: v (sherwood oil): v (ETHYLE ACETATE)=2: 1].
Embodiment 4:
Midbody
4Preparation
With reference to the method for embodiment 2, with 2,3-dichlorophenyl piperazine replaces the p-methylphenyl piperazine, with the bromoacetyl bromide reaction, gets yellow oil product (HPLC:99.0%).Rf=0.63 [single-point, developping agent: v (sherwood oil): v (ETHYLE ACETATE)=2: 1].
Embodiment 5:
Midbody
5Preparation
With reference to the method for embodiment 1, replace the 4-phenylpiperazine with 3-trifluoromethyl piperazine, with the chloroacetyl chloride reaction, get colorless oil product (HPLC:99.2%).Rf=0.57 [single-point, developping agent: v (sherwood oil): v (ETHYLE ACETATE)=2: 1].
Embodiment 6:
Midbody
6Preparation
In the reaction flask that stirring, condensing surface, TM are housed, add 2,3-dichlorophenyl piperazine 23.1g dissolves it with 50mL toluene, is cooled to-10 ℃ under stirring, and adds pyridine 23.7g.Chlorpromazine chloride 12.7g is dissolved in the 20mL toluene, slowly is added dropwise to reaction system, dropwise, continue reaction 3h (the flaggy demonstration reacts completely) down in 10 ℃.With 3 * 80mL water washing reaction solution, obtain toluene layer, use the SODIUM SULPHATE ANHYDROUS 99PCT thorough drying, to filter, toluene is to the greatest extent steamed in decompression, promptly gets faint yellow oily product 29.6g (HPLC:99.1%).Rf=0.64 [single-point, developping agent: v (sherwood oil): v (ETHYLE ACETATE)=2: 1].
Embodiment 7:
Midbody
7Preparation
With reference to the method for embodiment 6, replace 2 with 2-fluorophenyl piperazine, 3-dichlorophenyl piperazine with the bromopropionyl bromide reaction, gets yellow oil product (HPLC:98.8%).Rf=0.65 [single-point, developping agent: v (sherwood oil): v (ETHYLE ACETATE)=2: 1].
Embodiment 8:
(2-(4-phenylpiperazine-1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone (compound I-1) also for 5-
In the reaction flask that stirring, condensing surface, TM are housed, add 2.4g midbody 1, it is dissolved, stir adding Anhydrous potassium carbonate 4.3g down with the 10mL methylene dichloride.With 1.6g5,6,7,7a-THTP also [3,2-c] pyridines-2 (4H)-ketone adds reaction system in batches.Add, continue reaction 4h (the flaggy demonstration reacts completely) in refluxing down.With 3 * 15mL water washing reaction solution, obtain dichloromethane layer, use the SODIUM SULPHATE ANHYDROUS 99PCT thorough drying, to filter, methylene dichloride is to the greatest extent steamed in decompression, promptly gets yellow solid product (HPLC:98.4%).Rf=0.44 [single-point, developping agent: v (methylene dichloride): v (methyl alcohol)=1: 1].
1H?NMR(DMSO-d6，400MHz)δ：2.042～2.045(m，1H)，2.113～2.116(m，1H)，2.864～2.871(m，4H)，3.386～3.389(m，2H)，3.441～3.444(s，2H)，3.523～3.528(m，4H)，3.875～3.878(m，2H)，4.381～4.383(m，1H)，6.243(s，1H)，6.786～6.788(m，1H)，7.392～7.395(m，2H)，7.552～7.554(m，2H)。MS，m/Z：357.2(M)。
Embodiment 9:
(2-(4-p-methylphenyl piperazine-1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone (compound I-2) also for 5-
In the reaction flask that stirring, condensing surface, TM are housed, add the 3.0g midbody
2, with the 15mL trichloromethane it is dissolved, stir adding triethylamine 3.0g down.With 1.6g5,6,7,7a-THTP also [3,2-c] pyridines-2 (4H)-ketone adds reaction system in batches.Add, continue reaction 3h (the flaggy demonstration reacts completely) in refluxing down.With 3 * 20mL water washing reaction solution, obtain the trichloromethane layer, use the SODIUM SULPHATE ANHYDROUS 99PCT thorough drying, to filter, trichloromethane is to the greatest extent steamed in decompression, promptly gets light yellow solid product (HPLC:98.9%).Rf=0.45 [single-point, developping agent: v (methylene dichloride): v (methyl alcohol)=1: 1].MS，m/Z：371.2(M)。
Embodiment 10:
(2-(the adjacent fluorophenyl piperazine of 4--1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone (compound I-3) also for 5-
With reference to the method for embodiment 8, use midbody
3Replace midbody
1, with 5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-reactive ketone also, gets white solid product (HPLC:99.6%).Rf=0.50 [single-point, developping agent: v (methylene dichloride): v (methyl alcohol)=1: 1].
Embodiment 11:
(2-(4-(2, the 3-dichlorophenyl) piperazine-1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone (compound I-4) also for 5-
With reference to the method for embodiment 9, use midbody
4Replace midbody
2, with 5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-reactive ketone also, gets white solid product (HPLC:99.0%).Rf=0.48 [single-point, developping agent: v (methylene dichloride): v (methyl alcohol)=1: 1].
Embodiment 12:
(2-(4-(3-trifluoromethyl) piperazine-1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone (compound I-5) also for 5-
With reference to the method for embodiment 8, use midbody
5Replace midbody
1, with 5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-reactive ketone also, gets light yellow solid product (HPLC:98.3%).Rf=0.51 [single-point, developping agent: v (methylene dichloride): v (methyl alcohol)=1: 1].
Embodiment 13:
(3-(4-(2, the 3-dichlorophenyl) piperazine-1-yl)-3-oxopropyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone (compound I-6) also for 5-
In the reaction flask that stirring, condensing surface, TM are housed, add 3.2g midbody 6, it is dissolved, stir adding pyridine 2.4g down with 15mL toluene.With 1.6g 5,6,7,7a-THTP also [3,2-c] pyridines-2 (4H)-ketone adds reaction system in batches.Add, continue reaction 2h (the flaggy demonstration reacts completely) down in 90 ℃.With 3 * 20mL water washing reaction solution, obtain toluene layer, use the SODIUM SULPHATE ANHYDROUS 99PCT thorough drying, to filter, toluene is to the greatest extent steamed in decompression, promptly gets light yellow solid product (HPLC:98.9%).Rf=0.54 [single-point, developping agent: v (methylene dichloride): v (methyl alcohol)=1: 1].
1H?NMR(DMSO-d6，400MHz)δ：2.248～2.252(m，1H)，2.255～2.258(m，1H)，2.670～2.673(t，2H)，3.355～3.360(m，2H)，3.467～3.470(s，2H)，3.602～3.606(m，4H)，3.650～3.654(t，2H)，4.065～4.070(m，4H)，4.357～4.360(m，1H)，6.262(s，1H)，6.626～6.628(m，1H)，7.329～7.334(m，2H)。MS，m/Z：439.1(M)。
Embodiment 14:
(3-(4-(2-fluorophenyl) piperazine-1-yl)-3-oxopropyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone (compound I-7) also for 5-
With reference to the method for embodiment 14, use midbody
7Replace midbody
6, with 5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-reactive ketone also, gets light yellow solid product (HPLC:99.2%).Rf=0.45 [single-point, developping agent: v (methylene dichloride): v (methyl alcohol)=1: 1].
Embodiment 15:
Compound I-1 one-tenth hydrochloride: get I-1 solid product 2.0g, be dissolved in the 10mL anhydrous diethyl ether.Ice-water bath is cooled to 0 ℃, drip 25% hydrochloric acid diethyl ether solution to pH be 2, continue at stir about 1h under the ice-water bath.Filter, get light yellow solid.
Embodiment 16:
Compound I-3 one-tenth taurate: get I-3 solid product 2.0g, be dissolved in the 15mL absolute ethyl alcohol.Be heated to the back adding that refluxes and wait a mole taurine, continue at the about 2h of stirring reaction down that refluxes.Reaction finishes, and under room temperature, leaves standstill 24h.Filter, get white solid.
Embodiment 17:
Compound I-5 one-tenth vitriol: get I-5 solid product 2.5g, be dissolved in the 20mL anhydrous methanol.Ice-water bath is cooled to 5 ℃, drip concentrated sulfuric acid solution to pH be 3, continue at stir about 1h under the ice-water bath.Filter, get light yellow solid.
For the pharmaceutical composition of Thienopyridinone derivatives of the present invention is described more fully, following FORMULATION EXAMPLE is provided below, said embodiment only is used for explanation, rather than is used to limit scope of the present invention.Said preparation can use any active compound and the salt thereof in the The compounds of this invention, preferably uses the compound described in the embodiment 8～17.
Embodiment 18:
Prepare hard gelatin capsule with following compositions:
Consumption/capsule
Compound I-4 75mg
Pregelatinized Starch 100mg
Prist 4mg
Sodium starch glycolate 10mg
Magnesium Stearate 20mg
10% polyvidone ethanolic soln is an amount of
Preparation technology: supplementary material is dry in advance, and it is subsequent use to cross 100 mesh sieves.Press recipe quantity with the mentioned component mixing, cross 60 mesh sieves three times, add an amount of 10% polyvidone ethanol (95%) solution system softwood, cross 18 mesh sieves and granulate, 40 ℃ of dryings are crossed the whole grain of 16 mesh sieves, are packed in the hard gelatin capsule.
Embodiment 19:
Prepare tablet with following compositions:
Consumption/sheet
The hydrochloride 75mg of compound I-1
Starch 45mg
Microcrystalline Cellulose 40mg
CMS sodium salt 4.5mg
Magnesium Stearate 1mg
Talcum powder 1mg
Prist 3mg
Preparation technology: supplementary material is dry in advance, and it is subsequent use to cross 100 mesh sieves.Earlier with the abundant mixing of the auxiliary material of recipe quantity.Bulk drug is added in the auxiliary material to increase progressively dilution method, and each abundant mixing of added-time 2-3 time guarantees medicine and the abundant mixing of auxiliary material; Cross 20 mesh sieves, dry 2h in 55 ℃ of ventilated drying ovens, dried particle cross the arrangement of 16 mesh sieves; Measure midbody content, mix compressing tablet on tabletting machine.
Embodiment 20:
The preparation of injection liquid:
The taurate 45mg of compound I-3
Ucar 35 100mg
Polysorbate 80 is an amount of
Zero(ppm) water 300mL
Preparing method: get activeconstituents and join in the water for injection that dissolves sorbyl alcohol and Ucar 35, add medicinal basic adjusting pH value to 4～8 and make its dissolving.Add gac, whip attachment 30min, carbon removal, smart filter, embedding, sterilization.
Embodiment 21:
The preparation of injection lyophilized powder:
Vitriol 50 mg of compound I-5
Medicinal basic 0.1-7.0%
N.F,USP MANNITOL 55-80%
Preparing method: get activeconstituents and add water for injection, regulate pH value to 4～8 with medicinal basic and make its dissolving.Add N.F,USP MANNITOL again, carry out autoclaving by the requirement of injection, add gac, adopt filtering with microporous membrane, filtrating is carried out packing, adopts freeze-drying, makes loose block, seals, and promptly gets.
Claims (9)
1. the compound and the pharmacy acceptable salt thereof that have formula I structure:
Wherein:
n＝1，2；
R
1, R
2Be hydrogen, C
1-C
3Alkyl, halogen, halogenated methyl.
2. the compound and the pharmacy acceptable salt thereof of the formula I structure described in claim 1 is characterized in that:
n＝1；
R
1, R
2Be hydrogen, methyl, fluorine, chlorine, trifluoromethyl.
3. the compound of the formula I structure described in claim 1, representative:
(2-(4-phenylpiperazine-1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone also for I-1:5-;
(2-(4-p-methylphenyl piperazine-1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone also for I-2:5-;
(2-(the adjacent fluorophenyl piperazine of 4--1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone also for I-3:5-;
(2-(4-(2, the 3-dichlorophenyl) piperazine-1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone also for I-4:5-;
(2-(4-(3-trifluoromethyl) piperazine-1-yl)-2-oxoethyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone also for I-5:5-;
(3-(4-(2, the 3-dichlorophenyl) piperazine-1-yl)-3-oxopropyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone also for I-6:5-;
(3-(4-(2-fluorophenyl) piperazine-1-yl)-3-oxopropyl)-(5,6,7, the 7a-THTP is [3,2-c] pyridines-2 (4H)-ketone also for I-7:5-.
4. the compound of formula I structure as claimed in claim 1, its pharmacy acceptable salt is meant: compound and mineral acid, organic acid salify.
5. the compound of formula I structure as claimed in claim 4, its pharmacy acceptable salt is meant: hydrochloride, hydrobromate, hydriodate, vitriol, hydrosulfate, phosphoric acid salt, acetate, propionic salt, butyrates, lactic acid salt, mesylate, tosilate, PHENRAMINE MALEATE, benzoate, SUMATRIPTAN SUCCINATE, tartrate, Citrate trianion, fumarate, taurate.
6. the preparation method of the compound of claim 1 Chinese style I structure, it is characterized in that: substituted-piperazinyl compounds and halogen acyl halide are in methylene dichloride, trichloromethane or toluene, in the presence of triethylamine, pyridine, salt of wormwood, yellow soda ash, sodium hydrogencarbonate, saleratus, Pottasium Hydroxide, sodium hydroxide;-30 ℃～35 ℃ reactions make key intermediate; Midbody again with compound 5,6,7; 7a-THTP also [3; 2-c] pyridine-2 (4H)-ketone, in methylene dichloride, trichloromethane or toluene, in the presence of triethylamine, pyridine, salt of wormwood, yellow soda ash, sodium hydrogencarbonate, saleratus, Pottasium Hydroxide, sodium hydroxide acid binding agent; 0 ℃～90 ℃ reactions make I
Wherein X is a halogen.
7. the pharmaceutical composition of an anti-malignant tumor, it comprises compound or its salt and one or more pharmaceutical excipients of the formula I structure as claimed in claim 1 of treating significant quantity.
In the claim 1～5 compound of each described formula I structure and salt thereof in the application that is used to prepare medicine for resisting malignant tumors.
9. application as claimed in claim 8 is in the purposes that is used to prepare aspect treatment lung cancer, liver cancer, mammary cancer, the cancer of the stomach medicine.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101846423A CN101805355B (en) | 2010-05-27 | 2010-05-27 | Thienopyridone derivative, preparation method and uses thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010101846423A CN101805355B (en) | 2010-05-27 | 2010-05-27 | Thienopyridone derivative, preparation method and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101805355A CN101805355A (en) | 2010-08-18 |
| CN101805355B true CN101805355B (en) | 2012-07-04 |
Family
ID=42607321
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010101846423A Expired - Fee Related CN101805355B (en) | 2010-05-27 | 2010-05-27 | Thienopyridone derivative, preparation method and uses thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101805355B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103896962B (en) * | 2014-03-20 | 2016-09-14 | 天津药物研究院 | One class thienopyridine esters derivative containing substituted piperazinyl and its production and use |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681888A (en) * | 1984-11-16 | 1987-07-21 | Societe De Conseils De Recherches Et D'applications Scientifiques | Thienopyridine derivatives and anti-thrombotic compositions containing the same |
| CN101284838A (en) * | 2008-06-06 | 2008-10-15 | 天津药物研究院 | Ethylene imine derivates with thienopyridine, preparation method and applications thereof |
-
2010
- 2010-05-27 CN CN2010101846423A patent/CN101805355B/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681888A (en) * | 1984-11-16 | 1987-07-21 | Societe De Conseils De Recherches Et D'applications Scientifiques | Thienopyridine derivatives and anti-thrombotic compositions containing the same |
| CN101284838A (en) * | 2008-06-06 | 2008-10-15 | 天津药物研究院 | Ethylene imine derivates with thienopyridine, preparation method and applications thereof |
Non-Patent Citations (1)
| Title |
|---|
| 成碟等.含有取代哌嗪及哌啶结构的噻吩并吡啶类化合物的合成及活性研究.《中国药学杂志》.2009,第44卷(第22期),1752-1754. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101805355A (en) | 2010-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101361741B (en) | New anti-tumor use of iso-oxazoline derivates | |
| CN101845051B (en) | Nitrogen-containing heterocyclic thienopyridine compounds and preparation method and application thereof | |
| CN101863901B (en) | 2-(substituted phenyl)-2-(4,5,6,7-thiophane[3,2-c] pyridine-5(4H)-group)-N-substitute-acetamide as well as preparation method and application thereof | |
| CN102911118B (en) | Benzo-azepine type derivative and preparation method and purpose thereof | |
| CN101845052B (en) | Nitrogen-containing heterocyclic ring thienopyridine ketone derivative, preparation method and application thereof | |
| CN101974016A (en) | Amide compound and preparation method and applications thereof | |
| CN103864765B (en) | Benzazepine analog derivative containing five-membered ring, Preparation Method And The Use | |
| CN101805355B (en) | Thienopyridone derivative, preparation method and uses thereof | |
| CN104926804B (en) | One kind has compound, the preparation method and use of antitumor action | |
| CN101519423A (en) | Betulinic acid analogue and preparation method and application thereof | |
| CN102786458B (en) | Pyrrole formamide derivative, and preparation method and application thereof | |
| CN101863898B (en) | Thieno pyridinone derivative containing piperazidine and preparation method and applications thereof | |
| CN102276625B (en) | Thiadiazole derivative | |
| CN102276626B (en) | Isoxazole-containing compound | |
| CN105037345B (en) | Antitumoral compounds, preparation method and use | |
| CN102329327B (en) | Furan derivatives and preparation method and application thereof | |
| CN102417514B (en) | Pyridine derivatives, preparation method thereof, and purpose thereof | |
| CN102838652B (en) | A kind of oleanolic acid derivate with anticarcinogenesis and its production and use | |
| CN102796140A (en) | Phosphate-containing isoxazoline derivatives and their preparation method and use | |
| CN103304556B (en) | Schiff bases compounds containing chromene, Preparation Method And The Use | |
| CN101967154B (en) | Oxime compounds, preparation method and application thereof | |
| CN102358742B (en) | Thiazole compound with antitumor activity | |
| CN102268014A (en) | Condensed heteroaryl derivative and its preparation method and use | |
| CN101774976B (en) | Sulfonyl isoxazoline derivative and anti-tumor application | |
| CN101885726A (en) | New compound structure and preparation method and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20120704 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |